...Need to read what you cite netprophecy2. The first site your referred us to were five articles on CFS..from 1989...1993...1997...1998...and 2003..the latest being the Kansas four year study on CFS.
Let's look at that one. 800,000 people in the US thought to have CFS each year with only 20% accurately diagnosed. That's still 160,000 accurately diagnosed CFS patients per year where there is currently NO treatment. Say we get 30% of that market or 48,000 patients per year. Now here's the fun part...At a cost to treat of $1,000 per patient per year (which is a joke) we would take in gross 48,000,000 per year in sales. But $10,000 per year per patient would be more like it so try $480,000,000 in revenues. Let's say only 15% of the dignosed CFS patients use Ampligen. That's 24,000 patients at $1,000 per patient is $24,000,000 per year and at $10,000 per patient that's $240,000,000 per year.
you're very optimistic about you're calculation. At the other hand you have to Calculate Europe an the east to. Heb must be able to make 8000$(maybe 10k) for one treatment but i don't think they will treat 48000 patients a year. But even if they can treat 6000(i guess they'll do bether - i hope 10000) the first year, they can make 1$ a share. In that case the stock is worth 15$.